Enanta Pharmaceuticals, Inc.
$7.62-$0.36 (-4.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $341.1M
- P/E
- -4.2x
- EV / EBITDA
- -5.1x
- Revenue
- $65.3M
- Net margin
- -125.4%
- ROCE
- -36.8%
Price chart
Technical chartScreen technicals →-37.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -34.7%
- 3M
- -42.0%
- 6M
- -44.0%
- 1Y
- -37.2%
- 5Y
- -89.9%
52-week range
Day change -$0.36 (-4.5%) from $7.98 to $7.62 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in ENTA, bought on each weekday since 2021.
News & filings
What Enanta Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 81.9 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are 4.21 times current liabilities.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Read moreShow less
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 21.4M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $341.1M
- P/E
- -4.2x
- P/B
- 5.3x
- EV / EBITDA
- -5.1x
- EV / Sales
- 5.6x
- P/S
- 5.2x
- 52-week high
- $16.85
- 52-week low
- $7.62
Profitability
- Operating margin
- -130.7%
- Net margin
- -125.4%
- EBITDA margin
- -109.1%
- ROE
- -126.5%
- ROCE
- -36.8%
- ROIC
- -66.4%
- ROA
- -29.2%
- Asset turnover
- 0.23
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $65.3M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -3.4%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -8.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -29.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$32.2M
Solvency
- Current ratio
- 4.21
- Debt / Equity
- 0.89
- Debt / Assets
- 0.21
- CFO / Net profit
- 0.24
- Cash / Market cap
- 9.5%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $65.3M |
| Gross profit | $65.3M |
| Operating expenses | $150.7M |
| Research and development | $106.7M |
| Selling, general and administrative | $43.9M |
| Operating income | -$85.3M |
| Interest and other | $1.8M |
| Pretax income | -$83.5M |
| Tax and other | -$1.7M |
| Net income | -$81.9M |
Revenue and net profit
Revenue fell 3.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $86.2M | -$121.8M |
| FY2023 | $79.2M | -$133.8M |
| FY2024 | $67.6M | -$116.0M |
| FY2025 | $65.3M | -$81.9M |
Cash flows
FY2025: -$19.3M from operations, -$32.2M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$84.8M | -$86.9M |
| FY2023 | -$103.2M | -$112.2M |
| FY2024 | -$78.8M | -$96.7M |
| FY2025 | -$19.3M | -$32.2M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $65.3M-3.4%1Y
- EBITDA
- -$71.3M
- Net profit
- -$81.9M
- Cash from operations
- -$19.3M
- Free cash flow
- -$32.2M
- Revenue CAGR, 3Y
- -8.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $65.3M | -$71.3M | -$81.9M | -$32.2M | -126.5% | -3.4% | -29.4% |
Monthly returns
Month-by-month returns of ENTA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $280.7M |
| Current assets | $204.3M |
| Non-current assets | $76.4M |
| Liabilities | $216.0M |
| Current liabilities | $48.6M |
| Non-current liabilities | $167.5M |
| Equity | $64.7M |
| Paid-in capital | $469.8M |
| Retained earnings | -$404.9M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; ENTA highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Atea Pharmaceuticals, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc.ENTAthis company | $341.1M | -4.2x | 5.3x | -126.5% | -5.1x |
| Atea Pharmaceuticals, Inc.AVIR | $353.7M | -2.2x | 1.3x | -57.5% | -1.4x |
| Greenwich LifeSciences, Inc.GLSI | $347.1M | -22.0x | 137.0x | -623.1% | — |
| Larimar Therapeutics, Inc.LRMR | $341.8M | — | 4.4x | -212.2% | — |
| Verastem, Inc.VSTM | $339.2M | -1.6x | 5.9x | -366.2% | -1.1x |
| Simulations Plus, Inc.SLP | $336.4M | -5.2x | 2.7x | -51.9% | 20.8x |
| 908 Devices Inc.MASS | $333.5M | 17.1x | 2.3x | 13.6% | -12.6x |
| Abeona Therapeutics Inc.ABEO | $331.7M | 4.7x | 2.1x | 44.7% | 3.5x |
| Humacyte, Inc.HUMA | $330.8M | -8.1x | 106.4x | -1313.4% | -15.5x |
| Peer median | — | -2.2x | 3.5x | -134.8% | -1.3x |
Year-to-date ROI
ENTA since 1 January, against earlier years.
Historical volatility
ENTA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -143.7% |
| FY2023 | -173.2% |
| FY2024 | -179.9% |
| FY2025 | -130.7% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $65.3M |
| Operating expensesOperating Expense | $150.7M |
| Research and developmentResearch And Development | $106.7M |
| Selling, general and administrativeSelling General And Administration | $43.9M |
| Total expensesTotal Expenses | $150.7M |
| Operating incomeOperating Income | -$85.3M |
| Interest and other | |
| Pretax incomePretax Income | -$83.5M |
| TaxTax Provision | -$1.7M |
| Net incomeNet Income | -$81.9M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $280.7M |
| Current assetsCurrent Assets | $204.3M |
| Non-current assetsTotal Non Current Assets | $76.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $216.0M |
| Current liabilitiesCurrent Liabilities | $48.6M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $167.5M |
| EquityTotal Equity Gross Minority Interest | $64.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$19.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$19.3M |
| Net income, continuing operationsNet Income From Continuing Operations | -$81.9M |
| Depreciation and amortisationDepreciation And Amortization | $4.6M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $4.6M |
| Depreciation | $4.6M |
| Amortization of securitiesAmortization Of Securities | $500.0k |
| Stock-based compensationStock Based Compensation | $18.6M |
| Deferred taxDeferred Tax | — |
| Deferred income taxDeferred Income Tax | — |
| Operating gains and lossesOperating Gains Losses | $10.0k |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $10.0k |
| Change in working capitalChange In Working Capital | $39.9M |
| Other non-cash itemsOther Non Cash Items | -$950.0k |
| Investing cash flowInvesting Cash Flow | $40.4M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $40.4M |
| Capital expenditureCapital Expenditure | -$12.9M |
| Purchase of PP&EPurchase Of PPE | -$12.9M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$12.9M |
| Purchase of investmentsPurchase Of Investment | -$209.6M |
| Sale of investmentsSale Of Investment | $262.9M |
| Net investment purchases and salesNet Investment Purchase And Sale | $53.2M |
| Financing cash flowFinancing Cash Flow | -$26.6M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$26.6M |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | — |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | — |
| Stock options exercisedProceeds From Stock Option Exercised | $140.0k |
| Other financing chargesNet Other Financing Charges | -$26.8M |
| Change in cashChanges In Cash | -$5.5M |
| Cash at the start of the yearBeginning Cash Position | $41.2M |
| Cash at the end of the yearEnd Cash Position | $35.7M |
| Free cash flowFree Cash Flow | -$32.2M |
| Supplemental |
Learn while you research
Academy chapters picked for Enanta Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read